ESR3 Antibody

How should researchers validate ErbB3/HER3 antibody specificity in ligand-dependent vs. ligand-independent signaling models?

Validation requires orthogonal methods:

• Ligand-dependent systems: Use NRG1β-stimulated MCF7 cells. Measure phospho-HER3 (Y1276) inhibition via Western blot (WB) with antibodies like [EPR5808(2)] . Compare blocking efficacy against reference ligands (e.g., NRG1β EC50 = 10 ng/mL) .

• Ligand-independent systems: In HER2-amplified SKBR3 cells, assess HER3 phosphorylation (pY1289) suppression using antibodies like LJM716 . Validate via proximity ligation assays to confirm HER2-HER3 dimer disruption .

• Controls: Include siRNA-mediated HER3 knockdown and isotype-matched antibodies. For epitope specificity, use domain-swapped HER3 mutants (e.g., DIII-IV vs. DI-II) .

What methodologies resolve contradictions between ErbB3 antibody functional reports in oncogenic models?

Contradictions often arise from:

• Epitope heterogeneity: Compare antibodies targeting distinct domains (Table 1).

• Experimental context: Account for cell-specific HER2:HER3 ratios. For example, MAB3481 shows neutralization in NRG1-dependent MCF7 cells but fails in HER2-driven SKBR3 models .

• Phosphorylation kinetics: Perform time-course WB (0–120 min post-treatment) to capture transient signaling nodes like pAKT(S473) .

Table 1: Functional comparison of anti-HER3 antibodies

Which techniques optimize ErbB3 antibody dosing in xenograft studies?

• Pharmacodynamic modeling: Measure tumor HER3/AKT phosphorylation suppression at 24–72 hr post-injection .

• Biolayer interferometry: Determine tissue-specific binding kinetics (e.g., FcRn-mediated recycling impacts dosing intervals) .

• Combination therapy: For HER2+ models, co-administer trastuzumab with LJM716 at 10 mg/kg weekly, achieving synergistic tumor regression (p < 0.001 vs. monotherapy) .

How can cross-reactivity of ErbB3 antibodies with murine orthologs confound preclinical data?

• Species validation: Use QCM or SPR to compare binding to human vs. murine ErbB3-Fc (e.g., LJM716 binds both with KD = 220 pM vs. 2.7 nM) .

• Genetic models: Employ HER3-humanized mice or CRISPR-edited cell lines expressing chimeric receptors .

• Off-target profiling: Perform HuProt™ microarray screening (≥20,000 human proteins) to exclude polyreactivity .

What computational frameworks predict ErbB3 antibody efficacy against emerging HER3 somatic mutations?

• Molecular dynamics (MD) simulations: Model HER3 mutations (e.g., V104M, G284R) in complex with LJM716. Calculate binding energy changes (ΔΔG) using AMBER22 .

• Deep mutational scanning: Couple yeast display with NGS to map escape mutants under antibody pressure .

• AI-driven design: Utilize PALM-H3 to generate CDRH3 variants against mutant HER3 epitopes . Validate via BLI affinity measurements (kon/koff) .

Can ErbB3 antibodies discriminate between membrane-bound and soluble HER3 isoforms in clinical samples?

• Immuno-SRM: Develop antibodies targeting juxtamembrane epitopes (e.g., aa 1283–1323) . Pair with stable isotope-labeled peptides for mass spec quantification .

• Proximity assays: Use HER3/EGFR duplex NanoBRET to quantify membrane retention in live cells .

• Pre-analytical controls: Add metalloproteinase inhibitors (e.g., GM6001) to block ectodomain shedding during serum processing .

How do ErbB3 antibody repertoires evolve under immune pressure in oncologic microenvironments?

• Single-cell VDJ sequencing: Profile B cells from HER3+ tumor-infiltrating lymphocytes (TILs). Note CDRH3 clonal expansion (e.g., 74% of clones share ≥85% homology) .

• Affinity maturation analysis: Compare somatic hypermutation rates in framework vs. CDR regions using IgTreeSolver .

• Structural convergence: Align HER3-binding antibodies via ABodyBuilder2. Cluster paratopes using RMSD <2.0 Å .

What experimental pipelines validate AI-generated ErbB3 antibodies like PALM-H3?

• In silico screening:

  • Train A2binder on 11,000+ human antibody sequences .

  • Predict binding to HER3 epitopes (DIII-IV) with ΔG < −10 kcal/mol .

• Functional assays:

  • Test neutralizing activity in Ba/F3-HER2-HER3 cells (IC50 ≤ 0.03 µg/mL) .

  • Perform cryo-EM of antibody-HER3 complexes to verify epitope engagement .

How to quantify ErbB3 antibody internalization dynamics for ADC development?

• pH-sensitive probes: Label antibodies with pHrodo™ Red. Track endosomal trafficking via live-cell imaging (t1/2 = 15–45 min) .

• Cellular cytotoxicity: Co-culture HER3+ cells with PBMCs. Measure ADCC via LDH release (EC50 ≈ 0.1–1 nM) .

• Mathematical modeling: Apply two-compartment PK/PD models with parameters:

  • Internalization rate (kint) = 0.02–0.05 min⁻¹

  • Recycling efficiency (η) = 30–60%

Why do some ErbB3 antibodies exhibit paradoxical agonism in stromal cells?

• Receptor clustering: Use single-molecule localization microscopy (SMLM) to detect antibody-induced HER3 nanodomains (>50 receptors/µm²) .

• Downstream signaling: Profile phosphoproteomes (LC-MS/MS) to identify non-canonical pathways (e.g., Src-YAP1 activation) .

• In vivo correlates: Compare tumor vs. stromal pERK levels in PDX models treated with IgG 3-43 vs. LJM716 .